A method of treating a patient having Parkinson's Disease or parkinsonism, the method comprising administering to striatum of the patient cells in an amount effective to treat Parkinson's Disease or parkinsonism, wherein the cells are isolated from mammalian umbilical cord tissue substantially free of blood or are expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture, and require L-valine for growth; and wherein the cells do not produce CD117.
›2.↳ 1The method of claim 1, wherein the cells are induced in vitro to differentiate into neural lineage cells prior to administration.d2
The method of claim 1, wherein the cells are induced in vitro to differentiate into neural lineage cells prior to administration.
›3.↳ 1The method of claim 1, wherein the cells are administered with at least one other cell type of an astrocyte, oligodendrocyte, neuron, neural progenito…d2+1
The method of claim 1, wherein the cells are administered with at least one other cell type of an astrocyte, oligodendrocyte, neuron, neural progenitor, neural stem cell or other multipotent or pluripotent stem cell.
›4.↳ 3The method of claim 3, wherein the at least one other cell type is administered simultaneously with, or before, or after, the cells.d3
The method of claim 3, wherein the at least one other cell type is administered simultaneously with, or before, or after, the cells.
›5.↳ 1The method of claim 1, wherein the cells are administered by injection or infusion.d2
The method of claim 1, wherein the cells are administered by injection or infusion.
›6.↳ 1The method of claim 1, wherein the cells are administered encapsulated within an implantable device.d2
The method of claim 1, wherein the cells are administered encapsulated within an implantable device.
›7.↳ 1The method of claim 1, wherein the cells are administered by implantation of a matrix or scaffold containing the cells.d2
The method of claim 1, wherein the cells are administered by implantation of a matrix or scaffold containing the cells.
›8.↳ 1The method of claim 1, wherein the cells exert a trophic effect on the nervous system of the patient.d2
The method of claim 1, wherein the cells exert a trophic effect on the nervous system of the patient.
›9.↳ 1The method of claim 1, wherein the cells have the potential for at least about 40 doublings in culture.d2
The method of claim 1, wherein the cells have the potential for at least about 40 doublings in culture.
›10.↳ 1The method of claim 1, wherein the cells attach and expand on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel com…d2
The method of claim 1, wherein the cells attach and expand on a coated or uncoated tissue culture vessel, wherein the coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyomithine, vitronectin, or fibronectin.
›11.↳ 1The method of claim 1, wherein the cells produce at least one of tissue factor, vimentin, and alpha-smooth muscle actin.d2
The method of claim 1, wherein the cells produce at least one of tissue factor, vimentin, and alpha-smooth muscle actin.
›12.↳ 1The method of claim 1, wherein the cells produce at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C.d2
The method of claim 1, wherein the cells produce at least one of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C.
›13.↳ 1The method of claim 1, wherein the cells do not produce at least one of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP…d2
The method of claim 1, wherein the cells do not produce at least one of CD31, CD34, CD45, CD80, CD86, CD117, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ, as detected by flow cytometry.
›14.↳ 1The method of claim 1, wherein the cells exhibit increased expression, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an i…d2
The method of claim 1, wherein the cells exhibit increased expression, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, of at least one endogenous gene encoding interleukin 8; reticulon 1; chemokine (C—X—C motif) ligand 1 (melonoma growth stimulating activity, alpha); chemokine (C—X C motif) ligand 6 (granulocyte chemotactic protein 2); chemokine (C—X—C motif) ligand 3; tumor necrosis factor, alpha-induced protein 3; C-type lectin superfamily member 2; Wilms tumor 1; aldehyde dehydrogenase 1 family member A2; renin; oxidized low density lipoprotein receptor 1; Homo sapiens clone IMAGE:4179671; protein kinase C zeta; hypothetical protein DKFZp564F013; downregulated in ovarian cancer 1; and Homo sapiens gene from clone DKFZp547k1113.
›15.↳ 1The method of claim 1, wherein the cells exhibit reduced expression, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an ili…d2
The method of claim 1, wherein the cells exhibit reduced expression, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, of at least one endogenous gene encoding short stature homeobox 2; heat shock 27 kDa protein 2; chemokine (C—X—C motif) ligand 12 (stromal cell-derived factor 1); elastin (supravalvular aortic stenosis, Williams-Beuren syndrome); Homo sapiens mRNA; cDNA DKFZp586M2022 (from clone DKFZp586M2022); mesenchyme homeo box 2 (growth arrest-specific homeo box); sine oculis homeobox homolog 1 (Drosophila); crystallin, alpha B; disheveled associated activator of morphogenesis 2; DKFZP586B2420 protein; similar to neuralin 1; tetranectin (plasminogen binding protein); src homology three (SH3) and cysteine rich domain; cholesterol 25-hydroxylase; runt-related transcription factor 3; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer; frizzled homolog 7 (Drosophila); hypothetical gene BC008967; collagen, type VIII, alpha 1; tenascin C (hexabrachion); iroquois homeobox protein 5; hephaestin; integrin, beta 8; synaptic vesicle glycoprotein 2; neuroblastoma, suppression of tumorigenicity 1; insulin-like growth factor binding protein 2, 36kDa; Homo sapiens cDNA FLJ12280 fis, clone MAMMA1001744; cytokine receptor-like factor 1; potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; integrin, beta 7; transcriptional co-activator with PDZ-binding motif (TAZ); sine oculis homeobox homolog 2 (Drosophila); KIAA1034 protein; vesicle-associated membrane protein 5 (myobrevin); EGF-containing fibulin-like extracellular matrix protein 1; early growth response 3; distal-less homeo box 5; hypothetical protein FLJ20373; aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II); biglycan; transcriptional co-activator with PDZ-binding motif (TAZ); fibronectin 1; proenkephalin; integrin, beta-like 1 (with EGF-like repeat domains); 1-lomo sapiens mRNA full length insert eDNA clone EUROIMAGE 1968422; EphA3; KIAA0367 protein; natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C); hypothetical protein FLJ14054; Homo sapiens mRNA; cDNA DKFZp564B222 (from clone DKFZp564B222); BCL2/adenovirus EIB 19kDa interacting protein 3-like; AE binding protein 1; cytochrome c oxidase subunit VIla polypeptide 1 (muscle); similar to neuralin 1; B cell translocation gene 1; hypothetical protein FLJ23191; and DKFZp586L151.
›16.↳ 1The method of claim 1, wherein the cells secrete at least one of MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1a, RANTES, and TIMP1.d2
The method of claim 1, wherein the cells secrete at least one of MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO, MIP1a, RANTES, and TIMP1.
›17.↳ 1The method of claim 1, wherein the cells do not secrete at least one of TGF-beta2, ANG2, PDGFbb, MIP1b, I309, MDC, and VEGF, as detected by ELISA.d2
The method of claim 1, wherein the cells do not secrete at least one of TGF-beta2, ANG2, PDGFbb, MIP1b, I309, MDC, and VEGF, as detected by ELISA.
